SCHEMBL6329626

SCHEMBL6329626

COC(=O)c1ccccc1CC1CCC(=O)N(c2c(C)cccc2C)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.44
KDM4E B2RXH2 4/20 0.44
HTT P42858 2/20 0.44
GLA P06280 1/20 0.44
HPGD P15428 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
MAPK1 P28482 2/20 0.39
LMNA P02545 3/20 0.38
MAPT P10636 2/20 0.38
PKM P14618 1/20 0.38
P2RX7 Q99572 2/20 0.38
SIRT1 Q96EB6 1/20 0.38
KMT2A Q03164 3/20 0.38
GAA P10253 1/20 0.37
NR4A2 P43354 1/20 0.37
RECQL P46063 1/20 0.37
MEN1 O00255 1/20 0.37
TSHR P16473 2/20 0.36
XIAP P98170 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6328797 0.88 GRIK1 (0.39) ALDH1A1HTTP2RX7KMT2A
SCHEMBL6328210 0.81 P2RX7 (0.35) ALDH1A1KDM4EHTTL3MBTL1LMNA
SCHEMBL6328213 0.81 P2RX7 (0.35) ALDH1A1KDM4EHTTL3MBTL1LMNA
SCHEMBL6329240 0.80 P2RX7 (0.38) P2RX7KMT2AMEN1
SCHEMBL6335308 0.79 L3MBTL1 (0.42) ALDH1A1KDM4EGLAHPGDL3MBTL1
SCHEMBL6330392 0.74 SMN1; SMN2 (0.36) ALDH1A1L3MBTL1MAPTKMT2ATP53
SCHEMBL6330114 0.73 P2RX7 (0.43) ALDH1A1P2RX7
SCHEMBL3560662 0.72 NPSR1 (0.42) ALDH1A1L3MBTL1MAPTKMT2AGAA
SCHEMBL15058720 0.70 SCN1A (0.53) ALDH1A1KDM4EHPGDMAPK1LMNA
SCHEMBL6328576 0.70 MEN1 (0.37) L3MBTL1P2RX7KMT2AGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050085509-A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO. LTD. (JP) 2005-04-21 US claimed
EP-1447401-A1 PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-08-18 EP claimed
US-20050085509-A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO. LTD. (JP) 2005-04-21 US disclosed
EP-1447401-A1 PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085509-A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient MAPKAP1, MAPK1, MAPK8 ALDH1A1 2969/4885KDM4E 4383/4885HTT 2087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.